| Title |
The dexmedetomidine concentration required after remifentanil anesthesia is three-fold higher than that after fentanyl anesthesia or that for general sedation in the ICU
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, October 2014
|
| DOI | 10.2147/tcrm.s67211 |
| Pubmed ID | |
| Authors |
Takayuki Kunisawa, Kazuhiro Fujimoto, Atsushi Kurosawa, Michio Nagashima, Koji Matsui, Dai Hayashi, Kunihiko Yamamoto, Yuya Goto, Hiroaki Akutsu, Hiroshi Iwasaki |
| Abstract |
The general dexmedetomidine (DEX) concentration required for sedation of intensive care unit patients is considered to be approximately 0.7 ng/mL. However, higher DEX concentrations are considered to be required for sedation and/or pain management after major surgery using remifentanil. We determined the DEX concentration required after major surgery by using a target-controlled infusion (TCI) system for DEX. |
Mendeley readers
The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 20 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 20% |
| Other | 3 | 15% |
| Student > Ph. D. Student | 2 | 10% |
| Lecturer | 1 | 5% |
| Student > Doctoral Student | 1 | 5% |
| Other | 3 | 15% |
| Unknown | 6 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 40% |
| Nursing and Health Professions | 3 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 10% |
| Immunology and Microbiology | 1 | 5% |
| Engineering | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 5 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 October 2014.
All research outputs
#22,759,802
of 25,374,917 outputs
Outputs from Therapeutics and Clinical Risk Management
#1,204
of 1,323 outputs
Outputs of similar age
#227,190
of 265,645 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#10
of 12 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,645 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.